重组人脑利钠肽治疗顽固性心力衰竭的临床价值分析

目的 探讨重组人脑利钠肽治疗顽固性心力衰竭的临床价值。方法 选取医院顽固性心力衰竭患者84例（2018年7月—2020年7月），依照随机投掷法分为两组各42例，对照组采用常规治疗，观察组在此基础上采用重组人脑利钠肽治疗，比较两组患者治疗前后的心功能变化、疗效、心指数（cardiac index,CI）及氨基端前B型钠尿肽（N-terminal pro-B type natriuretic peptide,NTproBNP）水平、不良反应发生率。结果 治疗前两组的左心室射血分数（left ventricular ejection fraction,LVEF）、左室收缩末内径（left ventricular end systolic diameter,LVESD）、左室舒张末内径（left ventricular end diastolic diameter,LVEDD）比较差异无统计学意义（P> 0.05）；治疗后观察组的LVEF高于对照组，LVESD、LVEDD低于对照组，总有效率（92.86%）高于对照组（76.19%），差异有统计学意义（P <0.05）；治疗前，两组...

Clinical Value of Recombinant Brain Natriuretic Peptide in the Treatment of Refractory Heart Failure

Objective To investigate the clinical value of recombinant human brain natriuretic peptide in the treatment of refractory heart failure. Methods A total of 84 patients with refractory heart failure in our hospital(July 2018 to July 2020) were selected and randomly divided into two groups with 42 cases in each group. The control group was received conventional treatment, and the observation group was treated with recombinant human brain natriuretic peptide on this basis,and compared the changes of cardiac function, curative effect, cardiac index(CI), N-terminal pro-B type natriuretic peptide(NT-proBNP)levels, and incidence of adverse reactions between the two groups of patients before and after treatment. Results Left ventricular ejection fraction(LVEF), left ventricular end systolic diameter(LVESD), left ventricular end diastolic diameter(LVEDD) in the two groups before treatment was no significant difference(P > 0.05);after treatment, the LVEF of the observation group was higher than that of the control group, the LVESD and LVEDD of the observation group were lower than those of the control group, and the total effective rate(92.86%)was higher than that of the control group(76.19%), the difference was statistically significant(P < 0.05);before treatment, there was no significant difference in CI and NT-proBNP between the two groups(P > 0.05);after treatment, the CI in the two groups were higher than before treatment, and higher in the study group, the difference was statistically significant(P < 0.05);after treatment, the levels of NTproBNP in the two groups were lower, lower in the study group, the difference was statistically significant(P < 0.05). Compared with the control group(14.29%), the incidence of adverse reactions in the observation group(9.52%), and had no significant difference(P >0.05). Conclusion Recombinant human brain natriuretic peptide in the treatment of refractory heart failure can effectively improve the efficacy and improve the cardiac function of patients with good safety.